

Staff News at CCR

Announcement

(Photo: Courtesy of Scientific Publications, Graphics & Media)



Joel P. Schneider, Ph.D.

Joel Schneider has been named a CCR Deputy Director. He received his Ph.D. in organic chemistry from Texas A&M University. He then became a George W. Raiziss Postdoctoral Fellow at the University of Pennsylvania School of Medicine, Department of Biochemistry and Biophysics. He began his independent career at the University of Delaware as Assistant Professor of chemistry and biochemistry and was promoted to Associate and then Full Professor with a secondary appointment in materials science and engineering. He joined CCR in 2010 as Chief of the then newly established Chemical Biology Laboratory. His group's basic research entails designing soft materials, adhesives, and coatings for use in drug delivery and tissue repair. His group is especially interested in biomaterials formed via self-assembly mechanisms.

New Tenure-Track Scientists

(Photo: B. Branson)



Romina S. Goldszmid, Ph.D.

Romina Goldszmid is now an NIH Earl Stadtman Tenure-Track Investigator in CCR's Laboratory of Experimental Immunology. She received her Ph.D. from the University of Buenos Aires in Argentina. She conducted her postdoctoral research in the Laboratory of Parasitic Diseases at the National Institute of Allergy and Infectious Diseases. Goldszmid then joined the Laboratory of Experimental Immunology as a Staff Scientist. Her research focuses on linking the microbiome and mononuclear phagocyte development to cancer and infectious disease.

(Photo: Courtesy of C. Hoang)



Chuong D. Hoang, M.D.

Chuong Hoang joins CCR's Thoracic and Gastrointestinal Oncology Branch as a Tenure-Track Investigator. He received his medical degree from the University of Minnesota Medical School, where he stayed to complete clinical training in general surgery. Afterwards, he completed his cardiothoracic residency at the University of Pennsylvania. In 2008, he joined the faculty of Stanford University School of Medicine as an Assistant Professor. Choang was the Medical Director of the Stanford Cancer Center Tissue Bank. He also established an independent thoracic oncology laboratory investigating the metabolic derangements in lung cancer and microRNA interactions in mesothelioma. Currently, his research focuses on in-depth molecular interactions of microRNA and pathogenic gene networks in mesothelioma and other thoracic cancers to identify practical biomarkers or novel therapeutics targets.

(Photo: B. Branson)



Peter A. Pinto, M.D.

Peter Pinto is now a Tenure-Track Investigator in CCR's Urologic Oncology Branch. He obtained his medical degree from the State University of New York Upstate Medical School. Following a residency in urologic surgery at the Long Island Jewish Medical Center–Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins Hospital. Pinto then joined the Urologic Oncology Branch as a Staff Clinician and Head of the Prostate Cancer Section. His research focuses on vaccine strategies and molecularly-targeted therapeutic approaches to modulate cancer cell growth and survival, imaging and targeted registration of genitourinary tumors to improve diagnosis and treatment, and the minimally invasive treatment of urologic cancers, including high-intensity focused ultrasound and laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.

(Photo: B. Branson)



R. Taylor Ripley, M.D.

R. Taylor Ripley joins CCR's Thoracic and Gastrointestinal Oncology Branch as a Tenure-Track Investigator. He received his medical degree from Vanderbilt University. Ripley was a Surgical Oncology Fellow in CCR's Surgery Branch, and then went on to a general surgery residency at the University of Colorado. Most recently, he completed a cardiothoracic surgery fellowship at Memorial Sloan-Kettering Cancer Center with a focus in thoracic surgical oncology. Ripley is a thoracic surgeon and his research focuses on targeting the metabolism of esophageal cancer as a treatment strategy.